Metrikler
Yayın
59
Açık Erişim
10
BM Sürdürülebilir Kalkınma Amaçları
Eğitim Bilgileri
2010 - 2013
2010 - 2013Tıpta Yandal Uzmanlık
Hacettepe Üniversitesi, Tıp Fakültesi , Medikal Onkoloji , Türkiye
2004 - 2009
2004 - 2009Tıpta Uzmanlık
S.B.Dışkapı Yıldırım Beyazıt.E.A.H, İç Hastalıkları , İç Hastalıkları , Türkiye
1998 - 2004
1998 - 2004Yüksek Lisans
Gazi Üniversitesi, Tıp Fakültesi , Tıp Fakültesi , Türkiye
Yabancı Diller
B2 Orta Üstü
B2 Orta Üstüİngilizce
Araştırma Alanları
Tıp
Sağlık Bilimleri
Dahili Tıp Bilimleri
İç Hastalıkları
Onkoloji
Akademik Faaliyetlere Dayalı Araştırma Alanları
Avesis Araştırma Alanları
WoS Araştırma Alanları
Scopus Araştırma Alanları
Akademik Ünvanlar / Görevler
2016 - Devam Ediyor
2016 - Devam EdiyorYrd. Doç. Dr.
Hacettepe Üniversitesi, Kanser Enstitüsü, Klinik Onkoloji Anabilim Dalı
2013 - 2016
2013 - 2016Uzman
Hacettepe Üniversitesi, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümü
Akademi Dışı Deneyim
2013 - 2013
2013 - 2013MEDİKAL ONKOLOJİ UZMANI
PROF.DR.CELAL ERTUĞ ETİMESGUT DEVLET HASTANESİ, MEDİKAL ONKOLOJİ UZMANI
2009 - 2010
2009 - 2010DAHİLİYE UZMANI
PROF.DR.CELAL ERTUĞ ETİMESGUT DEVLET HASTANESİ, DAHİLİYE UZMANI
Makaleler
Tümü (40)
SCI-E, SSCI, AHCI (37)
SCI-E, SSCI, AHCI, ESCI (38)
ESCI (1)
Scopus (38)
TRDizin (4)
2025
20251. Sequential immunotherapy and bevacizumab treatments in glioblastoma multiforme: A case series and review of the literature
KERTMEN N., KAVGACI G., Koc I., PARLAK SAĞOL Ş., IŞIKAY A. İ., YAZICI G.
ONCOLOGY LETTERS
, sa.3, 2025 (SCI-Expanded, Scopus)
2025
20252. Evaluating Immunotherapy Responses in Neuro-Oncology for Glioblastoma and Brain Metastases: A Brief Review Featuring Three Cases
KERTMEN N., KAVGACI G., AKIN S., ÇOBAN ÇİFÇİ G., IŞIKAY A. İ., YAZICI G.
CANCER CONTROL
, 2025 (SCI-Expanded, Scopus)
2024
20243. Hypo-fractionated Stereotactic Re-Irradiation Outcomes For Recurrent Glioblastoma
Yilmaz M. T., KAHVECİOĞLU A., Mohammadipur S., Zorlu F., Oge K., KERTMEN N., et al.
RADIOTHERAPY AND ONCOLOGY
, 2024 (SCI-Expanded, Scopus)
2024
20244. Hypofractionated stereotactic re-irradiation for progressive glioblastoma: twelve years’ experience of a single center
Yilmaz M. T., KAHVECİOĞLU A., YAZICI G., Mohammadipour S., KERTMEN N., Cifci G. C., et al.
Journal of Neuro-Oncology
, cilt.167, sa.2, ss.295-303, 2024 (SCI-Expanded, Scopus)
2024
20245. Acute heart failure following pazopanib treatment: a literature review featuring two case reports
KERTMEN N., KAVGACI G., YILDIRIM H. Ç., DİZDAR Ö.
Anti-Cancer Drugs
, cilt.35, sa.3, ss.302-304, 2024 (SCI-Expanded, Scopus)
2023
20236. Seven-Year Single-Center Experience of the Efficacy and Safety of Ferric Carboxymaltose in Cancer Patients with Iron-Deficiency Anemia
AKTAŞ B. Y., ATA E. B., ÇEŞMECİ E., ÇAKIR İ. Y., Coşkunpınar M., TAHILLIOĞLU Y., et al.
Current Oncology
, cilt.30, sa.11, ss.9689-9700, 2023 (SCI-Expanded, Scopus)
2023
20237. Low-grade glial tumors: The experience of an oncology hospital in Türkiye
CEYLAN S., KERTMEN N., YAZICI G., KARS A.
Acta Medica
, cilt.54, sa.2, ss.151-156, 2023 (TRDizin)
2023
20238. SMART syndrome: a case report
Bozkurt S., Toprak B., YILDIRIM H. Ç., PARLAK SAĞOL Ş., GÜVEN D. C., KERTMEN N., et al.
ACTA NEUROLOGICA BELGICA
, cilt.123, sa.3, ss.1137-1140, 2023 (SCI-Expanded, Scopus)
2023
20239. KELIM score predicts outcome in patients with platinum-resistant/refractory recurrent ovarian cancer
KUŞ F., Guven D. C., YILDIRIM H. Ç., Chalabiyev E., AKYILDIZ A., Tatar O. D., et al.
Biomarkers in Medicine
, cilt.17, sa.7, ss.379-389, 2023 (SCI-Expanded, Scopus)
2023
202310. Optimal adjuvant treatment strategies for TNBC patients with residual disease after neoadjuvant treatment
Guven D. C., YILDIRIM H. Ç., KUŞ F., Erul E., KERTMEN N., DİZDAR Ö., et al.
Expert Review of Anticancer Therapy
, cilt.23, sa.10, ss.1049-1059, 2023 (SCI-Expanded, Scopus)
2022
202211. Lesson learned from the pandemic: Isolation and hygiene measures for COVID-19 could reduce the nosocomial infection rates in oncology wards
GÜVEN D. C., EROĞLU İ., Ismayilov R., ULUSOYDAN E., AKTEPE O. H., TELLİ DİZMAN G., et al.
JOURNAL OF ONCOLOGY PHARMACY PRACTICE
, cilt.28, sa.8, ss.1807-1811, 2022 (SCI-Expanded, Scopus)
2022
202212. Comparison of Clinical and Pathological Factors Affecting Early and Late Recurrences in Patients with Operable Breast Cancer
YEKEDÜZ E., DİZDAR Ö., KERTMEN N., AKSOY S.
JOURNAL OF CLINICAL MEDICINE
, cilt.11, sa.9, 2022 (SCI-Expanded, Scopus)
2022
202213. HER2-low breast cancer could be associated with an increased risk of brain metastasis
GÜVEN D. C., KAYA M. B., Fedai B., ÖZDEN M., YILDIRIM H. Ç., KÖSEMEHMETOĞLU K., et al.
INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY
, cilt.27, sa.2, ss.332-339, 2022 (SCI-Expanded, Scopus)
2022
202214. The use of fulvestrant before chemotherapy improves survival in hormone-positive breast cancer: a real-life study
GÜVEN D. C., YILDIRIM H. Ç., ERUL E., ŞAHİN T. K., ÇAKIR İ. Y., AKTEPE O. H., et al.
TURKISH JOURNAL OF MEDICAL SCIENCES
, cilt.52, sa.5, ss.1551-1558, 2022 (SCI-Expanded, Scopus, TRDizin)
2022
202215. Adjuvant treatment with paclitaxel plus trastuzumab for node-negative breast cancer: real-life experience
Diker O., AKTAŞ B. Y., Ak R., KÖYLÜ B., BAŞ O., TABAN H., et al.
FUTURE ONCOLOGY
, cilt.18, ss.323-331, 2022 (SCI-Expanded, Scopus)
2021
202116. The association of BMI and sarcopenia with survival in patients with glioblastoma multiforme
GÜVEN D. C., AKSUN M. S., ÇAKIR İ. Y., KILIÇKAP S., KERTMEN N.
FUTURE ONCOLOGY
, cilt.17, ss.4405-4413, 2021 (SCI-Expanded, Scopus)
2021
202117. Newly diagnosed cancer and the COVID-19 pandemic: tumour stage migration and higher early mortality
GÜVEN D. C., ŞAHİN T. K., YILDIRIM H. Ç., ÇEŞMECİ E., Incesu F. G. G., TAHILLIOĞLU Y., et al.
BMJ SUPPORTIVE & PALLIATIVE CARE
, 2021 (SCI-Expanded, Scopus)
2021
202118. Poorer baseline performance status is associated with increased thromboembolism risk in metastatic cancer patients treated with immunotherapy
GÜVEN D. C., AKSUN M. S., ŞAHİN T. K., AKTEPE O. H., YILDIRIM H. Ç., TABAN H., et al.
SUPPORTIVE CARE IN CANCER
, cilt.29, sa.9, ss.5417-5423, 2021 (SCI-Expanded, Scopus)
2021
202119. Sarcopenia and anthracycline cardiotoxicity in patients with cancer
BAŞ O., ERDEMİR A. G., ONUR M. R., ÖZER N., ŞENER Y. Z., AKSU S., et al.
BMJ SUPPORTIVE & PALLIATIVE CARE
, 2021 (SCI-Expanded, Scopus)
2021
202120. Does Combined Fractionated Stereotactic Radiotherapy and Immunotherapy Change the Outcome of Recurrent High-Grade Gliomas?
Sari S. Y., AKTAŞ B. Y., KERTMEN N., ELMALI A., Kilickap S., Oguz K. K., et al.
CUREUS
, cilt.13, sa.6, 2021 (ESCI)
2021
202121. Adjuvant treatment with paclitaxel plus trastuzumab for node negative human epidermal growth factor receptor 2-positive breast cancer: Real life experience
Diker O., AKTAŞ B. Y., Ak R., KÖYLÜ B., BAŞ O., Olgun P., et al.
CANCER RESEARCH
, cilt.81, sa.4, 2021 (SCI-Expanded, Scopus)
2020
202022. Pembrolizumab- and/or pazopanib-induced remitting seronegative symmetrical synovitis with pitting edema in a patient with renal cell carcinoma
BAŞ O., Ozbek A., Guven D., Aktepe O., KILIÇ L., KERTMEN N., et al.
JOURNAL OF ONCOLOGY PHARMACY PRACTICE
, cilt.26, sa.5, ss.1230-1233, 2020 (SCI-Expanded, Scopus)
2018
201823. Depression and anxiety in oncology nurses.
Keskin O., Oktay E., Turan M., Kertmen N., Tanriverdi O., Imamoglu G. I., et al.
JOURNAL OF CLINICAL ONCOLOGY
, cilt.36, sa.15, 2018 (SCI-Expanded, Scopus)
2017
201724. Comparison of prognosis and clinical features between synchronous bilateral and unilateral breast cancers
Karakas Y., KERTMEN N., LAÇİN Ş., Aslan A., DEMİR M., ATEŞ Ö., et al.
JOURNAL OF BUON
, cilt.22, sa.3, ss.623-627, 2017 (SCI-Expanded, Scopus)
2016
201625. Correlation of educational status and clinicopathological characteristics of breast cancer: a single center experience
Sarici F., BABACAN T., Buyukhatipoglu H., Balakan O., SEVER A. R., KERTMEN N., et al.
JOURNAL OF BUON
, cilt.21, sa.4, ss.826-831, 2016 (SCI-Expanded, Scopus)
2016
201626. Assessment of psychosocial factors and distress in women having adjuvant endocrine therapy for breast cancer: the relationship among emotional distress and patient and treatment-related factors
ATEŞ Ö., SOYLU C., BABACAN T., Sarici F., KERTMEN N., Allen D., et al.
SPRINGERPLUS
, cilt.5, 2016 (SCI-Expanded, Scopus)
2016
201627. Efficacy and safety of eribulin monotherapy in patients with heavily pretreated metastatic breast cancer
ATEŞ Ö., BABACAN T., KERTMEN N., Sarici F., Cenoli A., AKIN S., et al.
JOURNAL OF BUON
, cilt.21, sa.2, ss.375-381, 2016 (SCI-Expanded, Scopus)
2016
201628. Anthracyclin - Based Chemotherapy in Patients with Non-Hodgkin Lymphoma Aged Over 75
Sarici F., KERTMEN N., Aslan A. C., Tasdemir V., BABACAN T., KILIÇKAP S., et al.
UHOD-ULUSLARARASI HEMATOLOJI-ONKOLOJI DERGISI
, cilt.26, sa.2, ss.89-95, 2016 (SCI-Expanded, Scopus, TRDizin)
2015
201529. Efficacy of capecitabine monotherapy as the first-line treatment of metastatic HER2-negative breast cancer
BABACAN T., Efe O., Hasirci A. S., Demirci F., Buyukhatipoglu H., Balakan O., et al.
TUMORI J
, cilt.101, sa.4, ss.418-423, 2015 (SCI-Expanded, Scopus)
2015
201530. The lymph node ratio as an independent prognostic factor for non-metastatic node-positive breast cancer recurrence and mortality
Solak M., Turkoz F. P., Keskin O., AKSOY S., BABACAN T., Sarici F., et al.
JOURNAL OF BUON
, cilt.20, sa.3, ss.737-745, 2015 (SCI-Expanded, Scopus)
2015
201531. Chemotherapy might not be beneficial in lymph node-negative, hormone-positive, and HER2-negative breast cancer patients: a long-term retrospective analysis
BABACAN T., Buyukhatipoglu H., Balakan O., KERTMEN N., Suner A., Sarici F., et al.
JOURNAL OF BUON
, cilt.20, sa.2, ss.479-486, 2015 (SCI-Expanded, Scopus)
2015
201532. A retrospective analysis of adjuvant CAF, AC-T and TAC regimens in triple negative early stage breast cancer
Buyukhatipoglu H., BABACAN T., KERTMEN N., Balakan O., Suner A., ATEŞ Ö., et al.
JOURNAL OF BUON
, cilt.20, sa.1, ss.22-27, 2015 (SCI-Expanded, Scopus)
2015
201533. Comparison of three different induction regimens for nasopharyngeal cancer
KERTMEN N., AKSOY S., CENGİZ M., YAZICI G., KESKİN O., Babacan T., et al.
Asian Pacific Journal of Cancer Prevention
, cilt.16, sa.1, ss.59-63, 2015 (SCI-Expanded, Scopus)
2015
201534. Acquired C1 esterase inhibitor deficiency in a marginal zone lymphoma patient treated with rituximab
ATEŞ Ö., Sunar V., BABACAN T., AKIN S., KERTMEN N., Altundag K.
JOURNAL OF BUON
, cilt.20, sa.1, ss.349, 2015 (SCI-Expanded, Scopus)
2015
201535. A systemic late recurrence after the first operation in a patient diagnosed with early-stage breast cancer: the latest recurrence in the literature
Keskin O. D., KERTMEN N., Karakas Y., BABACAN T., ARIK Z., Altundag K., et al.
JOURNAL OF BUON
, cilt.20, sa.1, ss.348, 2015 (SCI-Expanded, Scopus)
2015
201536. Which sequence best protects the heart against trastuzumab and anthracycline toxicity An electron microscopy study in rats
KERTMEN N., AKSOY S., ÜNER A., ÖZGÜR Ö., keskin o., babacan t., et al.
Anticancer Research
, 2015 (SCI-Expanded, Scopus)
2015
201537. which sequence best protects the heart against trastuzumab and anthracycline toxicity? An electron microscopy study in rats
KERTMEN N.
Hacettepe Journal of Biology and Chemistry
, cilt.15, ss.1056-1058, 2015 (Scopus, TRDizin)
2015
201538. Molecular subtypes in patients with inflammatory breast cancer; A single center experience
KERTMEN N., BABACAN T., Keskin O., Solak M., Sarici F., AKIN S., et al.
JOURNAL OF BUON
, cilt.20, sa.1, ss.35-39, 2015 (SCI-Expanded, Scopus)
2015
201539. The effect of renin-angiotensin-system inhibition on survival and recurrence of N3+breast cancer patients
BABACAN T., Balakan O., Kuzan T. Y., Sarici F., Koca E., KERTMEN N., et al.
JOURNAL OF BUON
, cilt.20, sa.1, ss.50-56, 2015 (SCI-Expanded, Scopus)
2013
201340. Association between common risk factors and molecular subtypes in breast cancer patients
Turkoz F. P., Solak M., Petekkaya I., Keskin O., KERTMEN N., Sarici F., et al.
BREAST
, cilt.22, sa.3, ss.344-350, 2013 (SCI-Expanded, Scopus)
Hakemli Bilimsel Toplantılarda Yayımlanmış Bildiriler
2019
20191. Embedded outpatient palliative care service within the oncology clinic: Preliminary experience in Hacettepe Oncology Hospital
Guven D. C., AKTEPE O. H., Berk Z., Guner G., Taban H., AKTAŞ B. Y., et al.
44th Congress of the European-Society-for-Medical-Oncology (ESMO), Barcelona, İspanya, 27 Eylül - 01 Ekim 2019, cilt.30, (Özet Bildiri)
2019
20192. Clinicopathologic features of BRCA mutated breast cancer patients: Hacettepe experience
AKSOY S., DEĞİRMENCİLER R. F., AKTAŞ B. Y., Guven D. C., AKTEPE O. H., Guner G., et al.
44th Congress of the European-Society-for-Medical-Oncology (ESMO), Barcelona, İspanya, 27 Eylül - 01 Ekim 2019, cilt.30, (Özet Bildiri)
2018
20183. Depression and anxiety in oncology nurses.
KESKİN Ö., OKTAY E., TURAN M., KERTMEN N., TANRIVERDİ Ö., İMAMOĞLU İNANÇ G., et al.
2018 ASCO Annual Meeting, Amerika Birleşik Devletleri, 5 - 08 Haziran 2018, ss.18552, (Tam Metin Bildiri)
2017
20174. Onkoloji Hemşirelerinde depresyon ve anksiyete
KESKİN Ö., OKTAY E., TURAN M., KERTMEN N., TANRIVERDİ Ö., İMAMOĞLU G. İ., et al.
22.ULUSAL KANSER KONGRESİ, Türkiye, 19 - 23 Nisan 2017, (Özet Bildiri)
2017
20175. TRASTUZUMAB KARDİYOTOKSİSİTESİNİ İMMUNGLOBULİN /- STEROİD UYGULAMASI ÖNLEYEBİLİR Mİ?, TAVŞAN MODELİ HAYVAN DENEYİ
KERTMEN N., AKSOY S., ERMİŞ D. Y., KESKİN Ö., SOLAK M., ARIK Z., et al.
22. UKK, Türkiye, 19 - 23 Nisan 2017, (Özet Bildiri)
2016
20166. Intravenous ferric carboxymaltose treatment in cancer patients
ASLAN A., TAŞDEMİR V., KERTMEN N., DİZDAR Ö., AKSOY S.
2016 ASCO Annual Meeting, 29 Mayıs - 03 Haziran 2016, (Tam Metin Bildiri)
2016
20167. Clinicopathologic characteristics of patients with recurrent or metastatic synovial sarcoma
ATEŞ Ö., AKSOY S., YETER H. H., Akın S., KERTMEN N., DİZDAR Ö., et al.
2016 ASCO Annual Meeting, 29 Mayıs - 03 Haziran 2016, (Tam Metin Bildiri)
2015
20158. Kadri Altundag Taner Babacan Orhan Efe Ahmet S Hasırcı Fatih Demirci Hakan Buyukhatıpoglu Ozan Balakan Furkan Saim Sarıcı Neyran Kertmen Ece Esin Serkan Akin Ozturk Ates Sercan Aksoy Ali R Sever
ALTUNDAĞ M. K., Babacan T., EFE O., HASIRCI A. S., DEMİRCİ F., BUYUKHATİPOGLU H., et al.
2015 ASCO Annual Meeting, 29 Mayıs - 02 Haziran 2015, (Tam Metin Bildiri)
2015
20159. Efficacy and safety of eribulin monotherapy in patients with heavily pretreated metastatic breast cancer
Ateş Ö., Babacan T., SARICI F., KERTMEN N., CENOLİ A., Akın S., et al.
ASCO Annual Meeting, 29 Mayıs - 02 Haziran 2015, (Tam Metin Bildiri)
2015
201510. Neuroendocrine breast cancer A single center experience
TAŞDEMİR V., Kertmen N., CENOLİ A., KESKİN Ö., KARAKAS Y., Diker Ö., et al.
2015 ASCO Annual Meeting, 29 Mayıs - 02 Haziran 2015, (Tam Metin Bildiri)
2015
201511. Tumor locations significantly affect disease free survival and overall survival
BUYUKHATİPOGLU H., Babacan T., KERTMEN N., Ateş Ö., AKTAŞ G., ŞENDUR M. A. N., et al.
2015 ASCO Annual Meeting, 29 Mayıs - 02 Haziran 2015, (Tam Metin Bildiri)
2015
201512. Signet ring cell carcinoma of breast: Single center experience.
AKIN S., DIKER O., KERTMEN N., ATEŞ Ö., DİZDAR Ö., YALÇIN Ş., et al.
Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) / Clinical Science Symposium on Predicting and Improving Adverse Outcomes in Older Adults with Cancer, Illinois, Amerika Birleşik Devletleri, 29 Mayıs - 02 Haziran 2015, cilt.33, (Özet Bildiri)
2015
201513. Correlation of educational status and clinicopathological characteristics of breast cancer: A single center experience.
Diker O., Babacan T., Buyukhatipoglu H., Kertmen N., Balakan O., Sever A. R., et al.
Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) / Clinical Science Symposium on Predicting and Improving Adverse Outcomes in Older Adults with Cancer, Illinois, Amerika Birleşik Devletleri, 29 Mayıs - 02 Haziran 2015, cilt.33, (Özet Bildiri)
2015
201514. Efficacy of capecitabine monotherapy as the first-line treatment of metastatic HER-2 negative breast cancer.
Altundag K., Babacan T., Efe O., Hasirci A. S., Demirci F., Buyukhatipoglu H., et al.
Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) / Clinical Science Symposium on Predicting and Improving Adverse Outcomes in Older Adults with Cancer, Illinois, Amerika Birleşik Devletleri, 29 Mayıs - 02 Haziran 2015, cilt.33, (Özet Bildiri)
2014
201415. Comparison of three different induction regimen in nasopharyngeal cancer: CF versus DC versus DCF.
Kertmen N., Aksoy S., Cengiz M., Yazici G., Keskin O., Babacan T., et al.
50th Annual Meeting of the American-Society-of-Clinical-Oncology, Illinois, Amerika Birleşik Devletleri, 30 Mayıs - 03 Haziran 2014, cilt.32, (Özet Bildiri)
2014
201416. Which sequence prevents the heart from trastuzumab and anthracycline toxicity: Electron microscopy study in rats
Aksoy S., Kertmen N., ÜNER A., Sargon M., Ozkayar O., Keskin O., et al.
50th Annual Meeting of the American-Society-of-Clinical-Oncology, Illinois, Amerika Birleşik Devletleri, 30 Mayıs - 03 Haziran 2014, cilt.32, (Özet Bildiri)
2013
201317. Clinicopathologic characteristics of pure papillary breast carcinoma
Turkoz F. P., Solak M., Keskin O., Arik Z., Arslan C., Kertmen N., et al.
49th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Illinois, Amerika Birleşik Devletleri, 31 Mayıs - 04 Haziran 2013, cilt.31, (Özet Bildiri)
2013
201318. Association of the neutrophil to lymphocyte ratio with survival patients with in metastatic breast cancer.
Unlu O., Aygun S., Petekkaya H., Gecmez G., Roach E. C., Babacan T., et al.
49th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Illinois, Amerika Birleşik Devletleri, 31 Mayıs - 04 Haziran 2013, cilt.31, (Özet Bildiri)
2013
201319. The impact of adjuvant delayed radiotheraphy (RT) on survival in patients with resected periampullary adenocarcinomas.
Yalcin S., Kertmen N., Yuce D., Yildiz F., Hamaloglu E.
49th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Illinois, Amerika Birleşik Devletleri, 31 Mayıs - 04 Haziran 2013, cilt.31, (Özet Bildiri)